Agilon Health, Inc. (NYSE:AGL) Given Average Recommendation of “Hold” by Brokerages

Agilon Health, Inc. (NYSE:AGL) has been assigned a consensus recommendation of “Hold” from the seventeen brokerages that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $2.7083.

AGL has been the topic of a number of recent research reports. Wells Fargo & Company cut their price target on shares of Agilon Health from $1.50 to $1.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. Barclays lowered their target price on shares of Agilon Health from $1.50 to $1.00 and set an “underweight” rating on the stock in a research report on Thursday, November 6th. BTIG Research restated a “neutral” rating on shares of Agilon Health in a report on Friday, December 12th. Royal Bank Of Canada upgraded Agilon Health from a “hold” rating to a “moderate buy” rating in a research note on Wednesday, December 3rd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Agilon Health in a report on Wednesday, January 21st.

More Agilon Health News

Here are the key news stories impacting Agilon Health this week:

• Neutral Sentiment: Market commentary notes AGL is trading down and asks whether it is “Time to Sell?” — short market/analysis piece. AGL Trading Down 4% – Time to Sell?
• Negative Sentiment: The Gross Law Firm notifies Agilon shareholders to contact the firm before March 2, 2026 to discuss participation in the pending action. Gross Law Firm Notice
• Negative Sentiment: Faruqi & Faruqi LLP announces an investigation and urges affected investors to contact the firm (reminder of March 2 lead‑plaintiff deadline). Faruqi & Faruqi Alert
• Negative Sentiment: Rosen Law Firm reminds purchasers in the Feb. 26–Aug. 4, 2025 class period of the March 2 deadline in the securities class action it filed. Rosen Law Firm Reminder
• Negative Sentiment: Glancy Prongay & Murray LLP says investors who lost money can seek to lead the securities‑fraud class action against Agilon. Glancy Prongay & Murray Notice
• Negative Sentiment: Levi & Korsinsky notifies Agilon investors to contact the firm before March 2 to discuss their rights in the pending litigation. Levi & Korsinsky Notice
• Negative Sentiment: Kirby McInerney LLP reminds investors of the March 2 lead‑plaintiff deadline and the implications of not filing on time. Kirby McInerney Reminder
• Negative Sentiment: Bragar Eagel & Squire, Robbins LLP, Pomerantz, Bernstein Liebhard and other firms have issued alerts urging affected shareholders to contact them about the class action or lead‑plaintiff role. Bragar Eagel & Squire Alert
• Negative Sentiment: Robbins LLP and Pomerantz LLP similarly urge investors with losses to contact them about leading the suit; each filing increases outreach and potential class‑size. Robbins LLP Notice
• Negative Sentiment: Schall Law Firm and other firms remind investors of the pending securities complaint covering Feb. 26–Aug. 4, 2025 (opportunities to serve as lead plaintiff). Schall Law Firm Notice
• Negative Sentiment: Kaskela Law announces a stockholder investigation and references an earlier securities complaint covering purchases from 2021–2024 — signals potential broader governance/fiduciary concerns. Kaskela Investigation
• Negative Sentiment: Bronstein, Gewirtz & Grossman publicizes that a class action was filed alleging investor harm and invites affected shareholders to act. Bronstein Class Action Alert

Agilon Health Price Performance

Shares of Agilon Health stock opened at $0.82 on Thursday. The firm has a market cap of $340.37 million, a price-to-earnings ratio of -1.09 and a beta of 0.05. The stock has a 50-day simple moving average of $0.77 and a 200-day simple moving average of $1.04. Agilon Health has a 52-week low of $0.51 and a 52-week high of $6.08.

Agilon Health (NYSE:AGL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.09). The business had revenue of $1.44 billion for the quarter, compared to the consensus estimate of $1.43 billion. Agilon Health had a negative net margin of 5.24% and a negative return on equity of 75.92%. As a group, equities research analysts predict that Agilon Health will post -0.59 earnings per share for the current year.

Hedge Funds Weigh In On Agilon Health

A number of institutional investors have recently modified their holdings of AGL. CenterBook Partners LP lifted its stake in shares of Agilon Health by 492.4% in the third quarter. CenterBook Partners LP now owns 11,428,027 shares of the company’s stock worth $11,771,000 after buying an additional 9,499,012 shares during the last quarter. Geode Capital Management LLC raised its holdings in Agilon Health by 2.6% in the 2nd quarter. Geode Capital Management LLC now owns 7,156,466 shares of the company’s stock worth $16,462,000 after acquiring an additional 178,477 shares during the period. Bank of America Corp DE lifted its position in Agilon Health by 41.3% during the 3rd quarter. Bank of America Corp DE now owns 5,414,614 shares of the company’s stock worth $5,577,000 after acquiring an additional 1,581,284 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Agilon Health by 6.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,060,333 shares of the company’s stock worth $21,911,000 after acquiring an additional 311,158 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in Agilon Health by 68.8% during the third quarter. Jacobs Levy Equity Management Inc. now owns 3,099,850 shares of the company’s stock valued at $3,193,000 after acquiring an additional 1,263,677 shares during the period.

Agilon Health Company Profile

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.